pharma · Chronic Spontaneous Urticaria · Asthma
Novartis India
Novartis Pharmaceuticals
Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaP
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mumbai, IN
- Founded
- 1996
- Employees
- 2,240
- Programs
- 341
- Drugs
- 317
- Patents
- 0
CYTB323M12101B
Phase 2 · small molecule · Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement
CYTB323M12101B for Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code CYTB323M12101B
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement
- Status
- active
- Trials
- 1